Business Context and Reporting Period
This Form 8-K filing by AAR CORP. (NYSE: AIR) was submitted on July 13, 2021, reporting events occurring on July 12 and July 13, 2021. The filing addresses executive compensation adjustments necessitated by restrictions under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which the Company received financial support from in July 2020. These restrictions limit executive compensation until March 24, 2022.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments and retention awards.
Material Changes and Compensation Adjustments
Due to CARES Act restrictions, the Company reduced long-term equity awards for three Named Executive Officers (NEOs) for Fiscal Year 2022. The reductions are detailed below based on grant date fair value:
- John M. Holmes (President and CEO): Intended award of $3,380,000 was reduced to $1,280,078, a reduction of $2,099,922.
- Christopher A. Jessup (VP and Chief Commercial Officer): Intended award of $800,000 was reduced to $405,076, a reduction of $394,924.
- Eric S. Pachapa (VP, Controller and Chief Accounting Officer): Intended award of $403,000 was reduced to $260,045, a reduction of $142,955.
Additionally, the Company previously reduced Mr. Holmes' Fiscal Year 2021 equity grant by approximately 92,904 stock options and 53,537 restricted stock awards (RSAs) with an aggregate grant date fair value of $1,538,000.
Outlook, Management Commentary, and Retention Awards
To address the significant reduction in equity compensation and to retain Mr. Holmes in light of his leadership during the pandemic, the Board awarded him a deferred cash retention award of $1,000,000 on July 13, 2021. This award is contingent upon Mr. Holmes remaining continuously employed through the expiration of the CARES Act restricted period (March 24, 2022), unless paid earlier due to death or disability. Management indicated they may consider additional actions after the restricted period expires to maintain competitive compensation levels.
Key Facts for Investor Verification
- Verify the total value of deferred cash awards and their specific vesting conditions tied to the CARES Act expiration date.
- Confirm the impact of reduced equity grants on the total compensation package for the CEO and other NEOs relative to peer benchmarks.
- Monitor future filings for potential "make-whole" compensation adjustments once the CARES Act restrictions expire in March 2022.
- Note that this filing contains no operational or financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.